Progress on development of vaccines against 2019-nCoV
10.3760/cma.j.issn.1674-2397.2021.01.003
- VernacularTitle:新型冠状病毒疫苗的研究进展
- Author:
Keda CHEN
;
Chaonan LI
;
Danrong SHI
;
Hangping YAO
;
Lanjuan LI
- From:
Chinese Journal of Clinical Infectious Diseases
2021;14(1):13-20
- CountryChina
- Language:Chinese
-
Abstract:
Since the outbreak of COVID-19 caused by the 2019-nCoV (SARS-CoV-2), with its high pathogenicity and contagiousness, it has posed a serious threat to global public health security. Up to now, the pathogenesis of 2019-nCoV is unclear, and there is no effective treatment. Vaccine as one of the most effective strategies to prevent virus infection has become a hot area. Based on the current understanding of 2019-nCoV, the development of 2019-nCoV vaccines covers all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, etc. In this review, we focus on the candidate targets of the novel coronavirus, and the types, development status and progress of 2019-nCoV vaccines in order to provide information for further research and prevention.
